spacer
home > ebr > Summer 2004
PUBLICATIONS

European Biopharmaceutical Review

ebr
Summer 2004
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR.
   
Text
PDF
In her Editor's Letter, Dr Helen Abbott reviews the hot topics in this issue  
view
Science and Innovation
Beating Cancer Cells at their own Game: Professor Lindy Durrant of Scancell Ltd, Professor Stephen P Jackson of KuDOS Pharmaceuticals Ltd and Dr Klaus Giese of atugen AG, investigate the story  
view
Rajaram Sankaran, Industry Analyst with Frost & Sullivan's Technical Insights Division, reveals a Panacea in the Pipeline - Promising Drug Development Efforts Offer Hope to Cancer Patients  
view
Peter M Fischer, Head of Discovery Research at Cyclacel Limited, investigates Apoptosis and Chemotherapy: Helping Cancer Cells to Die  
view
bullet
Business Development and Financing
Mark Clement, Chief Executive of Merlin Biosciences, examines the current climate for Investing in European Life Sciences  
view
Dr Konrad Burk of ClinDescience GmbH, Dr William McCulloch of Gloucester Pharmaceuticals, Dr Alexander von Nieciecki of BioProof, and Dr Wolfgang Meyer and Dr Benno Rattel of GPC Biotech AG, ask Why is Scientific Due Diligence Essential in Drug Development?  
view
Effective responses to new investment opportunities are hampered by lack of preparation, contend Patrick Martin, Partner and Martin Finnegan, Senior Solicitor at McGrigors, in The IPO Window Reopens - Are you Ready?  
view
Nigel Sheail, Global Head, Strategic Alliances & Acquisitions at Roche Pharma, discusses Driving Productivity through Strategic Partnering  
view
bullet
Legal, Ethical and Regulatory
In Maximise the Return on Ethics Consultations by Minimising Deficit Thinking, Dr Andrew Smart, Sociology Research Officer for the Oxford Genetics Knowledge Park and Dr Kevin E Jones, Senior Research Associate at Brunel University, argue that deeply embedded assumptions about knowledge and expertise may curtail positive outcomes  
view
Dr Sandy Thomas, Director of the Nuffield Council on Bioethics, considers the ethical, legal, regulatory and social issues that may be raised as research progresses towards application in A Discussion of the Ethical Issues which Surround Pharmacogenetics  
view
Dr Delon Human, Secretary General of the World Medical Association, discusses the pre-eminent ethical guide on health care research in, The Declaration of Helsinki: Protecting Patient Rights in Biomedical Research Drug Discovery Technologies  
view
Dr Mark C Field, Department of Biological Sciences at Imperial College, London, and Dr Mark Carrington, Department of Biochemistry at the University of Cambridge, UK, explore Functional Genomics in Trypanosomes: Using RNA Interference to Assign Gene Function and Validate Drug Targets in Tropical Disease Agents  
view
Elucidation of genetic factors in causation and new treatments will be accelerated as Fully Automated Storage Creates an Open Source for Genetic Epidemiology, say Dr Martin Yuille, Chief Scientific Officer and Dr Cheng-Eng Ang, MRC DNA Banking Network Manager at MRC geneservice  
view
Stephanie Fulmer-Smentek, Senior R&D Research Scientist at Agilent Technologies Inc and Luis Lombardia, Research Associate at Centro Nacional de Investigaciones Oncologicas (CNIO), explore the Performance Comparison of 60-mer and 25-mer In Situ Synthesised Oligonucleotide Microarrays  
view
Dr Christian Bailly of Pierre Fabre, Dr David Wilson of Georgia State University, USA, and Dr Alan McWhirter of Biacore AB, assert that investigation of alternative drug targets is imperative in Optimising DNA-Binding Characteristics of Anticancer and Antiparasitic Drugs  
bullet
Biodevelopment and Manufacturing
In Drugs for Life - How 'Lifestyle' Medicines can Lead the Way to Healthy Profits, Chris Every, CEO of Enhance Biotech outlines the era of 'wellbeing' 88 Katherine Sacksteder, Director of Communications at Sequella, Inc, presents methods of navigating hurdles in the face of a tight budget, in Clinical Trial Challenges for Biotech Start-ups  
Adding Value in Exploratory Drug Development: Daryl Bendel, Managing Director of Charterhouse Clinical Research Unit Limited, and Rukhsana Ahsan, Laboratory Director of Clinical Trials Laboratory Services, explore The Clinical Trials Centre/Clinical Trials Laboratory Interface  
Michael R Hamrell, President of MORIAH Consultants, considers the continually evolving Preclinical Safety Assessment of Biologic Products  
Therapeutic proteins constitute a significant proportion of the global market, but experience and know-how is essential to high quality production, says Tony Hitchcock, Associate Director of Microbial Products at Cobra in Manufacturing Recombinant Proteins: Facing up to the Challenges of Making Tomorrow's Medicines  
bullet
Regional Focus: Scandinavia
Ylva Williams, Head of Life Sciences at the Invest in Sweden Agency, provides an insight into future challenges for Europe's fourth largest biotech country, in Sweden: Building Better Biotechnology  
Cross Border Research and Innovation in Medicon Valley - Stina Gestrelius and Anette Birck at Medicon Valley Academy offer an introduction to the region  
The knowledge-based growth strategy of Finland strongly supports research and development, explains Saara Hassinen, Assistant Director of Finnish Bioindustries in Biotechnology Industry in Finland  
Dr Beat E Glatthaar, Swiss General Manager of BioValley, reviews BioSquare 2004 in Basel - A Successful Get Together for Biotech in the BioValley  
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Kloeckner Pentaplast Announces Plans for New Lamination Facility


More info >>

White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>

Industry Events

7th annual Orphan Drugs and Rare Diseases UK

18-19 October 2017, Holiday Inn Kensington Forum, London

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This yearís theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement